MarketPulse
N

$NTRA

2 articles found
1 positive
0 negative
1 neutral
The Motley FoolThe Motley Fool··James Halley

Exelixis Expands Beyond Cabozantinib With FDA Approval and Robust Pipeline

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.
MRKNTRAEXELFDA approvalbiotech
The Motley FoolThe Motley Fool··Lee Samaha

Druckenmiller's Portfolio Reflects Conviction in Growth and AI Exposure

Druckenmiller concentrates holdings in Natera and TSMC, betting on genetic diagnostics growth and AI-driven semiconductor demand while balancing near-term profitability with long-term structural tailwinds.
TSMNTRAcapital expendituresemiconductor